



# FibroGen Mission DMD

---

**Jessica Charpentier, Clinical Program Manager**

**PARENT PROJECT MUSCULAR DYSTROPHY  
San Francisco Bay Area, CA - End Duchenne Tour  
November 3, 2018**

# FibroGen Overview

---

## Two innovative, first-in-class product platforms

- **Pamrevlumab** is the leader in anti-CTGF therapeutics
- **Roxadustat** is the leader in HIF-PHI therapeutics

# Pamrevlumab

**A novel investigational agent for treating fibrotic and fibro-proliferative diseases**

**Fully human monoclonal antibody to connective tissue growth factor (CTGF), a central mediator of fibrosis**

- **Duchenne Muscular Dystrophy (DMD)**
  - Phase 2 trial fully enrolled
- **Idiopathic Pulmonary Fibrosis (IPF)**
  - Positive Phase 2b safety and efficacy data presented at ERS 2017 and ATS 2018
  - Fast Track designation granted by FDA
  - Phase 3 trial design in progress – study start in 2019
- **Pancreatic Cancer (LAPC)**
  - Positive clinical data presented at ASCO 2018
  - Fast Track designation granted by FDA
  - Phase 3 trial design in progress – study start in 2019

# Pamrevlumab DMD Program


## Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to CTGF, in Non-Ambulatory Subjects with Duchenne Muscular Dystrophy

An open-label, single-arm study, in 21 non-ambulatory boys, age 12 years of age and older

- Objective: Estimate efficacy, evaluate safety and tolerability, and assess pharmacokinetics (PK)
- Endpoints:
  - Change in pulmonary function
  - Change in upper body muscle function tests
  - Change in muscle and cardiac fibrosis by MRI imaging
- Study Status: Fully enrolled and treatment is ongoing

# Study FGCL-3019-079 Design

- Each subject is receiving IV infusions of pamrevlumab (35 mg/kg every 2 weeks, not to exceed 150 cc/hour) for up to 156 weeks
- All subjects are closely monitored for safety



# Participating Centers

---

- UCSF Benioff Children's Hospital in San Francisco, CA
- Cincinnati Children's in Cincinnati, OH
- Washington University in St. Louis, MO
- Children's Hospital Colorado in Aurora, CO
- Rare Disease Research, Atlanta, GA
- Children's Hospital in Philadelphia, PA
- Boston's Children's Hospital in Boston, MA
- Shriners' Hospital for Children in Portland, OR
- UCLA School of Medicine in Los Angeles, CA
- Children's Medical Center in Dallas, TX

# Acknowledgements

---

- We would like to extend our appreciation to patients, their families, and the DMD community
- We would like to thank PPMD for the opportunity to participate

# Additional Information

---

For additional information regarding this study and participating sites, please contact:

Jessica Charpentier, FibroGen Clinical Program Manager

[jcharpentier@fibrogen.com](mailto:jcharpentier@fibrogen.com)

415-978-1346

or visit

[www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT02606136)



---

# Thank You!

